Learn More >

Ministry Status: Activation Status

Patient Evidence Submissions

Drug Review Schedule

The Ontario Public Drug Program is currently accepting submissions of patient evidence on the following drug products which will undergo review by the Committee to Evaluate Drugs within the next 12 months.

Drug products on this list include new chemical entities, new combination products and existing drug products with a new indication recently approved by Health Canada. At this time, drug products that are line extensions (such as additional strengths and new dosage forms) and drug products that are undergoing reconsideration (second review, etc.) will not be considered for patient submissions. The Ministry will re-evaluate this once additional experience on the process is gained.

For drug products accepted for Rapid Review process, best efforts will be made to provide maximal time for patient submissions. However, in view of the intent of Rapid Review, the review of a drug product accepted for Rapid Review will not be held if only to include presentation of patient submissions.

Registered patient groups are invited to provide patient evidence on any of the drugs listed below.

All submissions must be received by 5:00pm of the deadline date.

 

Generic Name Brand Name Manufacturer Indication / Type of Review Deadline for Patient Submissions
Tapentadol Nucynta Extended-Release Paladin Labs Inc. Pain, severe (CDR) September 19, 2018
Fluticasone propionate Aermony Respiclick Teva Canada Limited Asthma (CDR) July 18, 2018
Fluticasone propionate/ salmeterol Arbesda Respiclick Teva Canada Limited Asthma (CDR) July 18, 2018
Atezolizumab Tecentriq Hoffmann-La Roche Limited Non-small cell lung cancer, locally advanced or metastatic, after progression during/post chemotherapy (pCODR) June 27, 2018
Brodalumab Siliq Valeant Canada LP Psoriasis, plaque, moderate to severe (CDR) June 27, 2018
Netupitant/palonosetron Akynzeo Purdue Pharma Prevention of chemotherapy-induced nausea and vomiting (CDR) June 27, 2018
Pegfilgrastim Lapelga Apotex Inc. Prevention of febrile neutropenia in patients receiving myelosuppressive anti-neoplastic drugs (CDR) June 6, 2018
Infliximab Renflexis Merck Canada Inc. Rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis (CDR) May 30, 2018
Insulin glargine Basaglar Eli Lilly Canada Inc. Diabetes mellitus (request for funding of additional dosage format [KwikPen 80 units per injection] of an already listed product) May 30, 2018
Tofacitinib Xeljanz XR Pfizer Canada Inc. Rheumatoid arthritis (request for funding of additional dosage form [extended-release tablet] of an already listed product) May 30, 2018
Sebelipase alfa Kanuma Alexion Pharma Canada Lysosomal acid lipase deficiency (CDR) May 30, 2018
Rituximab Rituxan Hoffmann-La Roche Limited (Cancer Care Ontario submission) Induction treatment of newly diagnosed primary central nervous system lymphoma (in combination with thiotepa & high-dose methotrexate/cytarabine) May 28, 2018
Thiotepa Tepadina Adienne SA (Cancer Care Ontario submission) Induction treatment of newly diagnosed primary central nervous system lymphoma (in combination with rituximab & high-dose methotrexate/cytarabine) May 28, 2018
Cladribine Mavenclad EMD Serono Multiple sclerosis, relapsing (CDR) May 23, 2018
Dupilumab Dupixent Sanofi Aventis Canada Inc. Atopic dermatitis (CDR) May 23, 2018
Letermovir Prevymis Merck Canada Inc. Cytomegalovirus infection, prophylaxis (CDR) May 23, 2018
Ribociclib Kisqali Novartis Pharmaceuticals Canada Inc. Breast cancer, advanced or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (as initial endocrine therapy) (pCODR) May 23, 2018
Trifluridine/tipiracil Lonsurf Taiho Pharma Canada Inc. Colorectal cancer, metastatic (pCODR) May 23, 2018

See also:

Image:Pdf icon.gif To view PDF format files, you need to have Adobe Acrobat® Reader installed on your computer.
You can download this free software from the Adobe Web site.

For More Information

Call ServiceOntario, Infoline at:
1-866-532-3161 (Toll-free)
In Toronto, (416) 314-5518
TTY 1-800-387-5559.
In Toronto, TTY 416-327-4282
Hours of operation: Monday to Friday, 8:30am - 5:00pm